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Avoiding hypoglycemia is an important health and safety priority for all Type 2 diabetes mellitus 
(T2DM) patients. However, many diabetic patients do not adhere to a typical, American diet 
regimen. These individuals may consume fewer calories during religious, diet-restrictive activity 
or as they participate in weight-loss practices via a variety of popularized diets, including those 
that promote caloric restriction for varying periods. The modality for these diets is commonly 
referred to as “intermittent fasting” (IF). This case study concerns an obese woman with chronic 
diabetes with recent weight gain and who states she abstains from eating for “long periods of 
time.” Her lab indicators show poor blood glucose control over the past six months. She 
currently takes a sulfonylurea, which lowers blood glucose by increasing insulin release from 
pancreatic beta cells. Additionally, long-acting exogenous insulin is to be initiated. Given 
medically-sustained levels of insulin during periods of unknown, reduced caloric intake, serious 
concern arises that she may experience periods of hypoglycemia. In order to better understand 
how to best control blood glucose levels for this and other T2DM patients during periods of IF, a 
review of the literature was conducted. MEDLINE, CINAHL, PubMed and Cochrane databases 
were searched, and 21 articles were chosen for study inclusion. Popular literature was 
considered, as well. This research allows for a much clearer understanding of the effects of IF for 
general clinical application in T2DM and notes important measures for monitoring blood glucose 
levels during periods of IF and avoiding hypoglycemic episodes.   




 This case concerns a 65-year-old woman who has presented in the clinic for a six-month 
follow-up to monitor her diabetes, diagnosed 10 years prior. Her BMI is 36.5, and she has gained 
weight since her last visit. She checks her blood sugars infrequently with no consistent blood 
sugar log available. She is unconcerned that her a.m. blood sugars are elevated. She currently 
takes a biguanide/dipeptyl peptidase-IV inhibitor and a sulfonylurea. Lab parameters today are 
within normal limits aside from an abnormally high blood glucose level of 324, an HbA1c of 9.5 
and a minimally abnormal lipid panel. 
 During the course of the patient interview, the patient indicated that she eats infrequently 
and that she may abstain from eating for “long periods of time.” During these periods, she noted 
she does not consume sufficient carbohydrates, proteins and fats in spite of maintaining her 
diabetic medication regimen. These events, of course, raised concern for hypoglycemic episodes 
during periods of low caloric intake, especially given her use of a sulfonylurea (Ibrahim et al., 
2010). Additionally, given the decision to start this patient on long-acting insulin, the likelihood 
of hypoglycemic episodes could be further increased during calorie-restricted periods (American 
Diabetes Association, 2016). It is, therefore, critical that nurse practitioners have a clear 
understanding of IF and its effects in order to proactively manage patient health. 
 IF has been a functional reality for most of human history and currently presents in a 
variety of forms. Fung (2019) reminds us that IF has existed for many thousands of years in that 
our ancestors did not always have reliable access to food sources. IF has also been used in the 
last few millennia for religious purposes and, most recently, for its proposed health benefits. It is 
currently popularized as a diet form, which typically consists of minimal/restricted caloric intake 
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on one or more days per week or during a specific period of fasting each day (Leonard, 2018). It 
is, of course, important to understand how this type of diet may affect our diabetic patients. 
 In order to properly educate this patient concerning her diet and possible medication 
adjustments during periods of low caloric intake, it was necessary to undertake a review of the 
literature to understand more clearly how various types of fasting may affect glycemic levels in 
patients, especially in those patients prescribed a variety of oral and injected anti-hyperglycemic 
medications. This report addresses the effect of IF in patients with T2DM and discusses 
reasonable methods for patients to monitor blood sugar levels and avoid hypoglycemic episodes. 
Case Report 
History of Present Illness: 
Mrs. Jones is a 65-year-old patient here for a 6-month follow-up regarding her diabetes. 
No complaints, states she is compliant with medications. Does no regular exercise, works in the 
shop some during the week. Weight has gone up 5-10lbs, blames it on “winter, too cold to do 
much”. Checks blood sugars 2-3x per week, randomly, sometimes fasting, sometimes after 
eating. Denies any low blood sugars. Thinks the morning readings are in the 170-220 range. She 
saw ophthalmology 3 months ago for diabetic eye exam. 
 
Current medications: 
Glipizide 10 mg daily 
Lisinopril 10 mg daily 
Toprol XL 50 mg daily 
Zocor 20 mg daily 
Janumet 50-1000 BID 





Social: Retired school teacher, retired last year, lives at home with spouse. 2 adult children, no 
grandchildren 
 
Past Medical History: Obesity, Hyperlipidemia, DM Type 2 (diagnosed 10 years ago), Actinic 
Keratosis 
 
Past Surgical History: Cataract bilateral 2016, Colon polyp removal 2005, Right Carpal Tunnel 
2006 
 
EFFECT OF INTERMITTENT FASTING IN PATIENTS WITH T2DM 
 
6 
Tobacco Use: None 
 




PPSV23 - None 
PSV13 - None 
Tetanus- 2/2003 
Last colonoscopy: 2003 
 
Review of Systems: Head-to-toe review completed. Negative except as noted in HPI. 
 
Physical Exam: 
Vital Signs: 138/80, P – 72, R- 18.  Wt: 122 kg (269 lb), BMI: 36.5 
 
General examination, pertinent items: Obese, well-nourished in NAD, PERRLA, EOMI, RRR, 
no murmur, gallops/rubs; clear breath sounds; abd soft, non-tender, kidneys negative to 
percussion; no acanthosis nigricans noted; DTRs are symmetric and brisk; diabetic foot exam 
negative, pulses 2+. Exam negative unless otherwise noted. 
  
Labs: 
Creatinine Urine 30.00 - 259.00 mg/dL 101.82 
Microalbumin mg/L mg/L 22.17 
Microalbumin/Creatinine Ratio 0 - 30 mg/g 22 
 
Cholesterol 0 - 200 mg/dL 133 
Triglyceride 30 - 150 mg/dL 167 Abnormally high 
HDL 40 - 60 mg/dL 39 Abnormally low 
LDL 0 - 129 mg/dL 61 
Fasting Yes, No, Unknown Yes 
 
Hgb A1C – 9.5, 6 months ago – 8.1 
 
CMP: 
Glucose 70 - 100 mg/dL 324 Abnormally high 
BUN 7 - 18 mg/dL 16 
Creatinine 0.70 - 1.30 mg/dL 0.92 
BUN/Creatinine Ratio 15.0 - 20.0 17.4 
Sodium 136 - 145 meq/L 139 
Potassium 3.5 - 5.1 meq/L 4.3 
Chloride 98 - 107 meq/L 102 
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CO2 21 - 32 meq/L 28 
Anion Gap with K 6 - 20 meq/L 13 
Calcium 8.5 - 10.1 mg/dL 9.0 
Protein Total 6.4 - 8.2 g/dL 7.8 
Albumin 3.5 - 5.0 g/dL 4.7 
Alkaline Phosphatase 46 - 116 U/L 84 
AST - SGOT 15 - 37 U/L 19 
ALT - SGPT 12 - 78 U/L 30 
Bilirubin Total 0.2 - 1.0 mg/dL 1.1 
 
Assessment and Plan: 
E66.0  Obesity 
E78.5  Hyperlipidemia 
E11  DM Type 2 
 
Obesity: We reminded Mrs. Jones today of the need for diet modification and increased activity 
levels and that her obesity will continue to become more of a problem as time goes on. She 
agrees that she will increase her activity levels by taking over responsibilities for the family pet 
by walking the dog on a daily basis, morning and evening. She also agrees to visit with the 
dietitian for six visits over the next three months. We will follow up with her in three months to 
see if she feels that this is an effective strategy for her and to reassess her progress. She 
understands that her lipids and blood sugar levels will be positively affected if she is able to 
establish new dietary habits and lifestyle. 
 
Hyperlipidemia: Although her triglyceride levels are slightly elevated and her HDL is just below 
range, we will wait until she has tried the dietary/lifestyle intervention, and, if she is having 
success in the program, we will recheck labs in six months. We will continue the Zocor as 
ordered until that time. Refill ordered today. Should she feel the program is ineffective for her, 
we will recheck labs at that time and discuss possible changes in medication. 
 
DM Type 2: Given Mrs. Jones’ abnormally elevated blood sugar today and the change of her 
HbA1c to 9.5 from 8.1 six months ago, we agree it would be wise for her to start long acting 
insulin to better control her blood sugar levels. We will start with Lantus 10mg nightly and titrate 
up every three days by 2 units until her morning fasting blood sugar is <120. She states she is 
aware of low blood sugar symptoms and is able to use her glucose tabs or juices in the event of 
hypoglycemic episodes. We will follow up with a phone call in two weeks to monitor progress. 
Am placing a referral to the diabetic educator today for instructions on use of pen, injection sites, 
and lifestyle changes. She is also concerned about cost, so we are providing her information 
about resources available and will coordinate with DM educator with further questions. Our plan 
is to reduce diabetic medications, as possible. 
 
Immunizations/Screenings: Mrs. Jones is advised that she now meets the criteria for the 
pneumococcal vaccines. We will give PSV13 today, and she understands she will receive 
PPSV23 in one year. Tetanus booster also given today. Mrs. Jones continues to refuse follow-up 
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colonoscopy after discovering her polyp in 2005. She is, however, willing to complete a 
Cologuard test. We will order that today.  
 
Follow-up: She will continue to follow up with eye doctor for diabetic care. Next appointment in 
9 months. She will return to our clinic in three months for follow-up visit or sooner as needed. 
 
Literature Review 
Types and Number of Sources Reviewed 
 A search was conducted in MEDLINE, CINAHL, PubMed and the Cochrane Library for 
high-quality, original research articles via the Harley French Library at the University of North 
Dakota in order to gather information concerning the application of intermittent fasting in 
persons with T2DM. Search terms included “intermittent fasting," “calorie restriction,” “diabetes 
mellitus type 2,” or “type 2 diabetes.” Results were limited to English and publish dates after 
2014 for recency and relevance. Searches were limited to clinical trials with good results, where 
possible. This search resulted in a total of 116 articles, initially. 21 articles were retained based 
on a review of the respective abstracts and their ability to answer the clinical question of how 
intermittent fasting might affect patients with T2DM. These articles included one randomized 
controlled trial and three systematic reviews. Public opinion pieces were also researched in order 
to understand public perception of IF and to understand how it was being defined in layman's 
terms and within the diabetic community. 
Introduction to the Case 
 In that our patient was most likely engaging in various types of IF, whether intentional or 
not, she was placing herself at risk of dangerous hypoglycemic episodes in the context of two 
medications she was taking that increase the amount of insulin in her blood stream while she was 
simultaneously reducing dietary calories/glucose available for uptake into the cells. This case, 
therefore, reminds the provider of the unpredictability of individuals’ eating schedules as well as 
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the need to prepare for cases in which patients intentionally choose to reduce caloric intake for 
religious or weight-loss purposes. It is important to understand IF as presented in the literature 
and in the common vernacular, its typical effects in Type 2 diabetics, and how these patients can 
safely integrate this activity into their lifestyles while avoiding hypoglycemic episodes.  
Intermittent Fasting: Promising Results 
 Findings concerning IF diets are promising but are currently limited. Leonard (2018) 
describes several different commonly-used fasting diets: 12 to 16-hour fasts, fasting two days per 
week or on alternate days, one 24-hour fast per week, skipping specific meals, and limiting 
intake to primarily one meal per day. Mattson, Longo, and Harvie (2017) conclude that this type 
of intermittent and periodic fasting likely provides many beneficial effects on human health and 
disease, to include improvement in insulin resistance in diabetics. Arnason, Bowen, and Mansell 
(2017) agreed that IF may be a safe, tolerable dietary intervention that does improve key 
outcomes, including body weight, fasting glucose and postprandial variability. Additionally, 
from a financial perspective, Croppi and Tutt (2017) suggest that routine periodic fasting is 
essentially a no-cost therapy to both the patient and healthcare system. It can be seen then that IF 
has been found to provide a number of well-known health and economic benefits in several 
studies. However, when studying dietary patterns in general and the management of T2DM, 
Papamichou, Panagiotakos, and Itsiopoulos (2019) concluded that, while promising, IF lacked 
adequate research. In addition, Zubrzycki, Cierpka-Kmiec, Kmiec, and Wronska (2018) 
concluded that while caloric restriction did result in reductions in body fat mass and metabolic 
parameter improvements, they encountered a paucity of large scale RCTs on low calorie diets 
and IF. Therefore, while several studies do support IF practices, the current lack of data suggests 
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it might be valuable to understand similarities between IF and daily caloric restriction, which is a 
more standard means of diet management (Zuo et al., 2016). 
Comparing IF to Continuous Energy Restriction 
 By way of comparison, several authors studied intermittent energy restriction versus 
continuous (daily) energy restriction groups, both in terms of specific effects on HbA1c levels 
and, generally, in terms of sustained weight loss. Carter, Clifton, and Keogh (2016b; 2018) 
concluded that both groups offered a suitable treatment strategy causing significant reductions in 
HbA1c levels, which allowed for reduced medication dosages. Davis et al. (2016), Harris et al. 
(2018), and Zuo et al. (2016) all concluded that both groups experienced significant sustained 
weight loss. Zuo et al. (2016) also noted that an IF diet minimized weight regain and enhanced 
arterial compliance after one year. These findings could lead nurse practitioners to expect 
patients to accept and adopt IF dietary models as they prove more beneficial and effective over 
time. 
 Nonetheless, opinion does exist that standard, daily caloric restriction may be a preferred 
method of weight loss. In Doheny (2019), three endocrinologists expressed opinions that a 
standard low-calorie meal plan is probably safer and easier than IF. Additionally, it should be 
noted that even in popular literature (Diabetes Community UK, 2018), contributors state that 
while it is similar to other calorie restricted diets in terms of benefits, no long-term studies have 
been performed concerning IF and that individuals on medication could have significantly 
increased hypoglycemic episodes. Opinions, however, do not negate data gathered thus far, and, 
while continuous calorie restriction remains the typical means of dieting in the United States, 
important developments concerning IF are now occurring. 
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A Small but Important Case Study 
 Of specific interest in understanding IF is a small case study that gained recent attention 
due to its dramatic results. Furmli, Elmasry, Ramos, and Fung (2018) studied three adult males 
with chronic T2DM, multiple comorbidities, and who used at least 70 units of insulin daily. They 
were placed on an IF diet, and, over the course of 12 months, insulin resistance and HbA1c 
levels improved as they all lost weight. Importantly, they were all able to cease insulin therapy 
within 5 to 18 days of starting the program, and authors concluded that IF may aid in the 
remission of T2DM.  
In spite of the study parameters which required the three patients to be followed by the 
treating physician every two weeks on average, the leaders of two academic diabetic centers and 
one dietitian disagreed with the results as a safe option and encouraged medical consultation in 
addition to further research (Pratt, 2018). Scher (2018) and Tucker (2018) were supportive of the 
research conclusions, and Townley (2018) found the results encouraging. These disagreements 
remind nurse practitioners to remain aware of the potential for ideological differences due to 
conflicts of interest and encourage providers to seek unbiased data that points them in the 
direction of improving patient health. The status quo will require revision as our understanding 
evolves, and nurse practitioners must gather best data as it exists. 
 To that end, on a tangential but relevant note, two murine studies also showed interesting 
results applicable to the work of Furmli et al. (2018). Liu et al. (2017) showed that IF restored 
glucose tolerance, enhanced insulin secretion and beta cell survival and caused pancreatic 
regeneration in mice. In addition, Wei et al. (2018) showed that IF effectively intervenes in the 
progression of diabetes in mice. These results add useful data to the body of knowledge in this 
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area and could potentially lead to human studies that will reinforce the results of Furmli et al. 
(2018). The healthcare community awaits those studies. 
 As discussed, IF will require continued study, but early results are promising. Given the 
potential cost savings in medications due to a simple lifestyle change, the implications of Furmli 
et al. (2018) are enormous. As new research is conducted, providers are likely to continue to 
encounter both diabetic and non-diabetic patients who will engage in IF. However, in order to 
properly make use of the case at hand, specific clinical parameters must be evaluated as they are 
affected by IF. In this case, the critical parameter is hypoglycemia. 
Likelihood of Low Blood Sugar during Fasting Periods 
 A key clinical question one must ask is “how frequently will intermittent fasting cause 
significant hypoglycemia in most patients?” To that end, Corley et al. (2018) determined that 
fasting on either consecutive or nonconsecutive days increased the mean hypoglycemia rate from 
1.4 events in 12 weeks to 3.52 events in 12 weeks, which is significantly less than the mean rate 
of 1.74 events in five days as determined by Gehlaut et al. (2015) for most non-fasting Type 2 
diabetics. Additionally, Babineaux et al. (2015) determined that patients were able to fast for a 
greater number of days without acute complications by adjusting treatment regimens and 
following diet and blood glucose self-monitoring recommendations during Ramadan fasting. As 
an added benefit, Alharbi et al. (2017) concluded that Ramadan fasting did decrease fat mass in 
Type 2 diabetics. These studies point out that hypoglycemia occurs less frequently in most 
patients during intentional fasting periods when patients are closely monitoring blood sugars, 
medications, and caloric intake. Therefore, in that caloric restriction obviously necessitates 
careful monitoring of the above parameters, guidelines are useful for successful application of 
those monitoring tools. 
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Guidelines for Monitoring and Controlling Blood Sugars During Fasting 
 On days when patients engage in intermittent energy restriction (IER) (consuming 400 to 
800 kcal per day) Carter, Clifton, and Keogh (2016a) recommend taking oral medications as 
ordered, other than sulfonylureas. On IER days, they recommend discontinuation of 
sulfonylureas as well as insulin if baseline HbA1c is <10%. If HbA1c is >10%, the two 
medications are not adjusted. Also, in her article concerning daily fasting between dawn and 
sundown during Ramadan, Olansky (2017) notes, “Long-acting basal insulin should not require 
adjustment during fasting if the dose is not excessive” (p.1). The author writes that short-acting 
insulin analogues may still be taken with meals per anticipated carbohydrate intake, while insulin 
mixes should be avoided, and sulfonylureas should be reduced or eliminated during fasting 
hours. Lastly, she notes that blood glucose level should be monitored carefully during a fasting 
period, and patients are advised to break the fast if dangerously low glycemic levels occur. As 
providers learn and educate patients using these guidelines, they will assist patients in improving 
the likelihood of maintaining normoglycemic levels during fasting and non-fasting periods. 
Learning Points 
 In summarizing the main ideas of this case study, some key points that should be taken 
away from this discussion are as follows: 
• Low blood sugars occur rarely on intermittent fasting days. 
• In spite of infrequent hypoglycemia during fasting, blood sugars and dietary intake 
should be carefully monitored during these times. 
• Follow guidelines during fasting to minimize episodes of hypoglycemia.  
• Only sulfonylureas and short-acting insulin need to be reduced during periods of very 
low caloric intake. 
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While intermittent dietary restrictions may cause initial concern for hypoglycemia in 
Type 2 diabetics, research suggests that hypoglycemic events may be readily controlled via 
careful monitoring of physical parameters and medication dosing per guideline. Educating 
patients using these guidelines will allow them to more safely engage in IF as described and 
proactively avoid hypoglycemic episodes as they maintain a healthier lifestyle as T2DM patients.  
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